4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol | 680613-31-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol
• 英文别名: 1H-Indazole-1-ethanol, 6-chloro-5-fluoro-3-(4-hydroxyphenyl)-；4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)indazol-3-yl]phenol
• CAS: 680613-31-4
• 化学式: C₁₅H₁₂ClFN₂O₂
• 分子量: 306.724
• InChiKey: SBEVKBAZEXMZCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (4-Chloro-2,5-difluoro-phenyl)-(4-methoxy-phenyl)-methanone 在 吡啶 、 三溴化硼 作用下， 以 二氯甲烷 、 环己烷 为溶剂， 反应 149.0h， 生成 4-[6-chloro-5-fluoro-1-(2-hydroxyethyl)-1H-indazol-3-yl]phenol
  参考文献：
  名称：

  Synthesis and Activity of Substituted 4-(Indazol-3-yl)phenols as Pathway-Selective Estrogen Receptor Ligands Useful in the Treatment of Rheumatoid Arthritis

  摘要：

  Pathway-selective ligands for the estrogen receptor (ER) inhibit NF-kappaB-mediated inflammatory gene expression causing a reduction of cytokines, chemokines, adhesion molecules, and inflammatory enzymes. SAR development of a series of 4-(indazol-3-yl)phenols has led to the identification of WAY-169916 an orally active nonsteroidal ligand with the potential use in the treatment of rheumatoid arthritis without the classical proliferative effects associated with estrogens.

  DOI：

  10.1021/jm049194+

文献信息

• Substituted 4-(Indazol-3-yl)phenols
  申请人：Steffan J. Robert

  公开号：US20070225349A1

  公开（公告）日：2007-09-27

  This invention provides compound of formulae I or II having the structure wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

  该发明提供了式I或II的化合物，其结构为： 其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如规范中所定义，或其药学上可接受的盐，用于治疗疾病的炎症成分，特别适用于治疗动脉硬化、心肌梗塞、充血性心力衰竭、炎症性肠病、关节炎、II型糖尿病以及多发性硬化和风湿性关节炎等自身免疫疾病。
• SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：Wyeth

  公开号：EP1542976B1

  公开（公告）日：2009-02-04
• Synthesis and Activity of Substituted 4-(Indazol-3-yl)phenols as Pathway-Selective Estrogen Receptor Ligands Useful in the Treatment of Rheumatoid Arthritis
  作者：Robert J. Steffan、Edward Matelan、Mark A. Ashwell、William J. Moore、William R. Solvibile、Eugene Trybulski、Christopher C. Chadwick、Susan Chippari、Thomas Kenney、Amy Eckert、Lisa Borges-Marcucci、James C. Keith、Zhang Xu、Lydia Mosyak、Douglas C. Harnish

  DOI：10.1021/jm049194+

  日期：2004.12.1

  Pathway-selective ligands for the estrogen receptor (ER) inhibit NF-kappaB-mediated inflammatory gene expression causing a reduction of cytokines, chemokines, adhesion molecules, and inflammatory enzymes. SAR development of a series of 4-(indazol-3-yl)phenols has led to the identification of WAY-169916 an orally active nonsteroidal ligand with the potential use in the treatment of rheumatoid arthritis without the classical proliferative effects associated with estrogens.